Hatteras Venture Partners
Venture capitalResearch Triangle · Seed–Series C · 24 people tracked
Also known as HATTERAS VENTURE ADVISORS III, LLC · HATTERAS VENTURE ADVISORS IV, LLC · HATTERAS VENTURE ADVISORS V LLC · HATTERAS VENTURE ADVISORS VI, LLC · HATTERAS VENTURE ADVISORS VII, LLC
Investment thesis
Hatteras Venture Partners invests in high-quality science and teams pursuing breakthrough ideas with significant potential impact for patients. The firm prioritizes therapeutic and diagnostic advances as well as companies disrupting the healthcare status quo. Beyond providing capital, it supports portfolio companies with team recruitment, portfolio strategy, business development, and regulatory and clinical planning, aiming to build transformational companies that reach value inflection quickly and efficiently. Based in North Carolina's Research Triangle, the firm is a leader in the Southeast while maintaining a broad North American investment footprint, drawing on over 25 years of experience across more than 100 companies.
Source: firm website, verified Aug 25, 2026.
Team · 24 people
from the firm's website & curated & public directories
Founder mafia
4 people who came through Hatteras Venture Partners went on to found or lead other companies.
What they invest in
from 74 of 130 portfolio companiesBiotech ×47Healthtech ×47Medical Devices ×30Digital Health ×17AI & Machine Learning ×10Deep Tech ×9SaaS ×6Consumer ×4
HQs:United States×69United Kingdom×1
Who they back
founder profiles across 13 portfolio companiesFounding team size:solo founder×62 founders×63 founders×1
Investments · 130 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 42024 · 52023 · 22022 · 42021 · 42020 · 42018 · 22017 · 22016 · 12015 · 32014 · 137 dated
Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.
BiotechHealthtechMedical Devices
Co-investorsCardinal Partners
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Margaret FitzPatrick(Director)Patricia Martin(Director)
Co-investorsAdjuvant CapitalBioRock VenturesFlucas VenturesMountain Group CapitalRA Capital
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)Nadim Yared(Executive Officer, Director)Dean Bruhn-Ding(Executive Officer)John Brintnall(Executive Officer)Liz Galle(Executive Officer)
BoardGeoff Pardo(Director)
Co-investorsNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios CapitalVensana Capital
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersMRL Ventures FundNextech Invest+3 more
Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases.
BiotechAustin, US
Josiah Hornblower(President/CEO)
BoardWalter Loewenbaum(Director)
Co-investorsEcoR1 CapitalOrbiMedT. Rowe Price
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.
BiotechHealthtechMedical DevicesRaleigh, US
THOMAS MATHERS(Executive Officer, Director)James Shaffer(Executive Officer, Director)Thomas Mathers(Executive Officer, Director)John Fahy(Director)in
BoardChristy Shaffer(Director)inRishi Gupta(Director)
Co-investorsOrbiMedCanaan PartnersPappas Capital
Avivomed is a medical device company developing minimally invasive neuromodulation therapies for patients with obstructive sleep apnea.
BiotechDeep TechHealthtechMedical DevicesRoseville, US
Lynn Elliott(Co-Founder)Mudit Jain(Co-Founder)Paul Mazanec(Chief Executive Officer)Stephen Masson(Executive Officer, Director)
BoardTheresa C. Pappas(Director)Ketan Patel(Director)in
Co-investorsTreo Ventures, LlcF-Prime Capital
Boomerang Medical develops a bioelectric neuromodulation device to treat bowel urgency symptoms in patients with ulcerative colitis and other inflammatory bowel disease.
BiotechDigital HealthMedical DevicesMountain View, US
Co-investorsArboretum Ventures
Contego Medical develops the Neuroguard IEP System, a 3-in-1 carotid stenting device combining a carotid stent, dilation balloon, and integrated embolic protection with a 40-micron filter to reduce stroke and cognitive impairment from microembolization.
HardwareHealthtechMedical DevicesRaleigh, US
Ravish Sachar(CEO & Founder)Paul Sanders(Chief Operating Officer)
Co-investorsLightstone VenturesAmzak HealthMountain Group CapitalUS Venture Partners
iRiva Medical is a development-stage medical device company building neuromodulation technology platforms to treat patients with chronic diseases.
BiotechHealthtechMedical DevicesMinneapolis, US
Mudit K. Jain(Co-Founder and Chairman of the Board)Lynn Elliott(Co-Founder and Director)Steve Masson(President & CEO)
Co-investorsTreo Ventures, LlcF-Prime Capital
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)Schalon Newton(Executive Officer)
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsExSight VenturesSolasta VenturesAccess BiotechnologyBios PartnersCorrelation VenturesFemHealth Ventures+2 more
BEKhealth builds an AI-powered platform that reads structured and unstructured EHR data to support clinical trial feasibility, patient matching, and real-world data generation.
AI & Machine LearningDigital HealthHealthtechBranford, US
Joshua Ransom(Executive Officer)David Levin(Chief Executive Officer)inJosh Brown(Chief Technology Officer)inScott Caflisch(Chief Information Security Officer)inJeff Graham(Chief Data Officer)inJennifer Stacey(Chief Operating Officer)in
Board seatJohn Crumpler· per SEC Form D
Co-investorsConnecticut InnovationsExcelerate Health VenturesMartin Ventures
Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.
AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US
Amit K. Gupta(Executive Officer, Director)Omer Inan(Co-founder, Chief Scientific Officer)Andrew Carek(Co-founder, Chief Technical Officer)Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan, PhD(Co-founder, Chief Scientific Officer)in
Board seatLauren Pierce Flickinger· per SEC Form D
Co-investorsBayMed Venture PartnersBroadview VenturesCross-Border Impact VenturesLaerdal Million Lives FundOSF VenturesPortal Innovations
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.
BiotechHealthtechMedical DevicesAlpharetta, US
Mark Prausnitz(Director)Charles Deignan(Executive Officer)Glenn Noronha(Executive Officer)Daniel H. White(Executive Officer, Director)
BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in
Board seatClay ThorpChristy Shaffer· per SEC Form D
Co-investorsHEALTHCARE ROYALTY PARTNERSMountain Group CapitalSolasta VenturesHatteras
BiotechBrisbane, US
John S. Patton, Ph.D(Executive Officer, Director)Tyler Martin, M.D.(Executive Officer, Director)Greg Zante(Executive Officer)Lisa E. Porter, M.D.(Executive Officer)
BoardAdam Stern(Director)Augustine P.Y. Chow, M.D.(Director)
Board seatKenneth B. Lee, Jr.· per SEC Form D · $15M raise · filed Jun 2020
Healthcare-enabling research organization that embeds clinical trials into everyday care using electronic health record data.
HealthtechAustin, US
Chad Moore(President)John Potthoff(Chief Executive Officer)inJacylyn Bodmer(Chief Information Officer)Karen Flaherty(Vice President, Finance)Amy Staedtler(Chief Legal Officer)Scott Treiber(Chief Operating Officer)
Board seatJohn Crumpler· per SEC Form D
Co-investorsExcelerate Health VenturesNoro-Moseley PartnersNorwest Venture PartnersShumway Capital
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Mark A. Velleca(Executive Officer, Director)inTimothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)Seth Rudnick(Director)Ron Laufer(Director)Michael Gutch(Director)
Board seatClay ThorpChristy Shaffer· per SEC Form D
Co-investorsLumira VenturesMountain Group CapitalRA CapitalSolasta Ventures
GeneCentric develops ExpressCT, a fragmentomics technology that extracts gene expression measurements from circulating tumor DNA sequencing data to enable expression-based biomarkers for cancer diagnostics and precision oncology.
BiotechDigital HealthMedical DevicesDurham, US
MICHAEL MILBURN(Executive Officer, Director)CHARLES PEROU(Director)David Neil Hayes(Executive Officer, Director)Charles Perou(Director)Arnold Levine(Director)
Board seatMyla Lai-GoldmanClay Thorp· per SEC Form D
Co-investorsIAG Capital Partners
Franklin, US
Justin Neece(Executive Officer, Director)Martin Seeger(Executive Officer)
BoardMark Tomaino(Director)
Board seatFred Goldwater· per SEC Form D · $5M raise · filed Dec 2018
ilumivu builds software platforms for behavioral and clinical research, including tools for running clinical trials, patient engagement, and multisite collaborative research using wearable and mobile technology.
AI & Machine LearningDigital HealthHealthtechMental HealthSaaSFairview, US
Mark Tuomenoksa(Co-Founder & Chief Technology Officer)inLauren Pierce Flickinger(Chief Executive Officer)inKate Rahimzadeh(Chief Operating Officer)Sandeep Goel(Executive Officer, Director, Promoter)
Board seatLauren Pierce Flickinger· per SEC Form D
BiotechRtp, US
Matthew Cohen(Director)Anil Goyal(Executive Officer, Director)Lev Osherovich(Director)Jenny Ting(Director)Mark Vellaca(Director)
BoardBenjamin Scruggs(Director)
Board seatMark Velleca· per SEC Form D · $4M raise · filed Jan 2023
HealthtechNew York, US
Kate Hershov(Director)Kim Chilman-Blair(Executive Officer, Director)Mitzie Garland(Executive Officer)
BoardFredric Eshelman(Director)Jonathan Comerford(Director)
Board seatJohn Crumpler· per SEC Form D · $2.3M raise · filed Aug 2020
BiotechBoston, US
Robin Y. Smith(Executive Officer, Director, Promoter)Kate Blanchard(Executive Officer, Director, Promoter)
BoardDoug Jamison(Director)Jonathan Meltzer(Director)
Board seatClay Thorp· per SEC Form D · $28.7M raise · filed Sep 2020
PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.
BiotechHealthtechMedical DevicesMalvern, US
Ashutosh Chilkoti(Director)Joel Sussman(Executive Officer)Jonathan Mow(Executive Officer, Director)
BoardJames Barrett(Director)Michael Gutch(Director)Justin Klein(Director)
Board seatRobert IngramClay Thorp· per SEC Form D
Co-investorsMountain Group CapitalNew Enterprise Associates (NEA)
BiotechDurham, US
Heather Madsen(Ms. Madsen is a director and the CEO of the issuer.)William Wiesler(Executive Officer, Director)
Board seatHolden ThorpClay ThorpChristy Shaffer· per SEC Form D · $2.5M raise · filed Nov 2025
StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.
BiotechHealthtechDurham, US
Aravind Asokan(Director)Mavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)Patrick Ritschel(Executive Officer, Director, Promoter)
Board seatClay ThorpMike Dial· per SEC Form D
Co-investorsPontifax Venture Capital
Durham, US
Neil Moore(Executive Officer)Robert J. Schotzinger, M.D., Ph.D.(Executive Officer, Director)
BoardSteven D. Weinstein(Director)Kristopher A. Wood(Director)Adrian Howd(Director)
Board seatRobert Ingram· per SEC Form D
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Board seatClay Thorp· per SEC Form D
Co-investorsAtlas VentureLightstone VenturesVida VenturesLongwood Fund
HealthtechHenrico, US
Will Saunders(Executive Officer, Director)Robert Schultz(Director)Mark Tripodi(Executive Officer)Tania Grant(Director)John Mark Ramsey(Director)
Board seatLauren Pierce Flickinger· per SEC Form D · $5.6M raise · filed Aug 2026
Co-investorsZiegler Link-age Funds
Wildflower Health offers a modular suite of software and services for women's health, combining a digital patient engagement app, a national network of human health advocates and specialists, and value-based care payment model support.
Digital HealthFemTechHealthtechSan Francisco, US
Leah Sparks(CEO & Founder)Kim Russell(Chief Financial Officer of Issuer)
BoardDan Galles(Director of Issuer)inEzra Mehlman(Director of Issuer)Ralph Sabin(Director of Issuer)in
Board seatJohn Crumpler· per SEC Form D
Co-investorsAllumia VenturesEcho Health VenturesHealthtech Capital
410 Medical makes LifeFlow, a hand-operated rapid infuser that lets clinicians quickly deliver blood or fluids to critically ill patients needing volume resuscitation.
HardwareHealthtechMedical DevicesDurham, US
Mark Donald Piehl(Executive Officer, Director)KYLE CHENET(Executive Officer, Director)
BoardJEFF TERRELL(Director)inSTANLEY D. LYNALL(Director)FRED GOLDWATER(Director)inMAYANK TANEJA(Director)in
Co-investorsBallad VenturesCU Healthcare Innovation FundDuke Capital PartnersOSF VenturesWolfpack Investor NetworkBios Partners
Altis Biosystems builds RepliGut®, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling.
BiotechDeep TechHealthtechMedical DevicesDurham, US
Christopher Sims(Executive Officer)Jimmy Smedley(Executive Officer)Samuel Franklin(Director)Joseph McMahon(Director)Michael Biron(Executive Officer, Director)
BoardChristopher Perkins(Director)
Co-investorsAtlanta Technology AngelsCentral Texas Angel NetworkCheckmate Capital Group LLCIDEA NCJohnson Venture PartnersVentureSouth
Co-investorsArboretum VenturesBayMed Venture PartnersBroadview VenturesCatalyst Health Ventures
Co-investorsLightstone VenturesOUP (Osage University Partners)
Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases.
BiotechMedical Devices
Co-investorsLightstone VenturesSofinnova Ventures
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Iaso Ventures+7 more
Durham, US
Kevin Schulman(Director)Seth W. Glickman(Executive Officer, Director)Richard Staelin(Executive Officer, Director)Seth Glickman(Director)David Levin(Executive Officer, Director)
BoardDonald Holzworth(Director)
Caidya is a contract research organization (CRO) that combines scientific, medical, and operational expertise to manage complex clinical development and cross-border trials.
BiotechDigital HealthHealthtech
Co-investorsVivo Capital
Canopy Lawn Care provides science-based residential lawn care services using natural ingredients like coffee grounds, amino acids, probiotics, and sea kelp to promote soil health and reduce reliance on synthetic fertilizers and pesticides.
AgTechCleantechConsumer
Co-investorsElevate Innovation Partners
Carpe sells antiperspirant and sweatcare products designed to reduce underarm sweat and odor for consumers, offering customized options based on a customer quiz.
ConsumerDirect to ConsumerWellness & Fitness
Co-investorsLaunchCapital
Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials.
BiotechDigital HealthHealthtechMorrisville, US
Mark Ubert(Executive Officer)Jesse Watson(Director)Brian Carney(Director)Jeff L. Williams(Executive Officer, Director)Melissa Daniels(Director)Christopher K. Porter(Executive Officer)
Co-investorsCreathor VenturesOUP (Osage University Partners)
Durham, US
Nathaniel C. Brinn(Director)Joseph F. Trepanier(Executive Officer)Andy Strayer(Director)M. Denis Connaghan(Executive Officer, Director)Gary Tyson(Director)Kenneth B. Lee(Director)
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.
BiotechDeep TechHealthtechHatfield, US
Lauren Kaskiel(Executive Officer)Robert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)
BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)
Co-investorsNew Enterprise Associates (NEA)
Clinical-stage biotech developing in vivo immune programming via mRNA-LNP platform.
Co-investors8VC
Co-investorsArboretum Ventures
Emergo Therapeutics develops drugs designed to modulate inflammatory responses by reducing the production and secretion of inflammatory cytokines, targeting damaging symptoms across a range of diseases.
BiotechHealthtechDurham, US
Robin Hyde-DeRuyscher(Founder)inMoise Khayrallah(CEO)inMargaret Powell(Director)Robert Helmedag(Director)John E. Bailey, Jr.(Director)
Co-investorsRex Health VenturesWolfpack Investor Network
Entegrion develops a point-of-care viscoelastic coagulation monitoring system (VCM) for rapid hemostasis assessment in clinical settings including trauma, surgery, and obstetrics.
BiotechDefense TechHealthtechMedical DevicesDurham, US
Bert Valada(President and CEO)Richard Martin(Executive Officer)Susan Reyer(Executive Officer)Michael Galiger(Executive Officer)John Mowell(Director)Thomas Edwards(Director)
Raleigh, US
Thaddeus W. Tarkington(Executive Officer, Director)Kevin J. Barry(Executive Officer, Director)Tom Lotrecchiano(Director)
BoardSteve Dauphin(Director)David E. Gardner(Director)inLister Delgado(Director)
Co-investorsCofounders CapitalElevate Innovation PartnersArsenal
Co-investorsElevate Innovation Partners
GoCheck Kids offers a smartphone-based MultiScreener that combines photoscreening, visual acuity, and pure tone audiometry to screen young children for vision and hearing problems.
Digital HealthHealthtechMedical Devices
David Huang(Founder)
Co-investorsAloft VCFCA Venture PartnersMucker Capital
HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.
BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB
Thomas Davison(Executive Officer, Director)M. Christine Gibbons(Executive Officer, Director)Wen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)
Co-investorsAlpha Wave GlobalAmzak HealthEarly Stage Partners, LPHealthQuest CapitalLumira VenturesMichigan Capital Network+2 more
Qoniq combines tailored AI analytics with expert guidance to help Medical Affairs and Scientific Affairs teams analyze large volumes of publications and datasets, surface patterns, and generate industry-standard, well-sourced scientific reports.
AI & Machine LearningBiotechHealthtech
Co-investorsSteelSky VenturesFusion
Palo Alto, US
Gregory Kostello(Executive Officer)Lana Feng(Executive Officer, Director)Susan Shiff(Executive Officer, Director)William Dai(Director)
BoardAndrew Schwab(Director)John Crumpler(Director)in
Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions.
BiotechDigital Health
Garner, US
Richard R. Hawkins(President/CEO)
BoardMoshe Meidan(Manager)Ken Campbell(Manager)Sarid M. Shefet(Manager)
Co-investorsWolfpack Investor Network
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
Co-investorsCape Fear BioCapitalEshelman Ventures, LLCHatteras
InnAVasc develops a vascular access graft for hemodialysis, featuring self-sealing pods and puncture-resistant backplates that guide dialysis needle placement to reduce needle-injury and bleeding complications.
BiotechHardwareHealthtechMedical DevicesDurham, US
Shawn Gage(Executive Officer)Jeffrey Lawson(Executive Officer, Director)Joseph Knight(Executive Officer, Director)Roberto Duane Manson(Executive Officer)
BoardDani Bolognesi(Director)
Co-investorsDuke Capital Partners
InvestorFlow provides a CRM and investor portal with AI-assisted workflows for fundraising, deal execution, and investor relations.
AI & Machine LearningFintechSaaS
Co-investorsAmbina PartnersGrandBanks CapitalKPS Capital PartnersMerit Capital PartnersSteelSky Ventures
IVEAcare develops neuromodulation and bioelectronics therapies, implantable medical devices aimed at treating chronic conditions for large patient populations.
Deep TechHealthtechMedical DevicesRoseville, US
Todd Kerkow(Co-Founder, President and CEO)inMudit Jain(Co-Founder and Chairman of the Board)Lynn(Co-Founder and Board Member)inCorey Dishmon(Director)Robert Greenberg(Director)
BoardKirk Nielsen(Director)in
Co-investorsTreo Ventures, LlcVensana Capital
Jumo Health provides patient experience solutions for clinical trials, focusing on building patient readiness through education and behavioral systems rather than traditional recruitment.
Digital HealthHealthtech
Co-investorsExcelerate Health VenturesFalfurrias
Wilmington, US
Robert B Preville(Executive Officer, Director)Robert Kaiser(Executive Officer, Director)
BoardRandy Swartz(Director)
Co-investorsVentureSouth
Ladder operates a marketplace that connects construction employers with skilled trade workers for hiring and staffing needs.
Construction TechMarketplacesPropTechAtlanta, US
Co-investorsY CombinatorCREATE HEALTH VENTURESGROOVE CAPITALJumpstart CapitalNina Capital
Melo Creative is a website design studio offering minimalist Showit website design and SEO strategy services for photographers and small business creatives.
Creator EconomyMarketing Tech
Mercy develops blood-based tests for early cancer detection using its patented Mercy Halo platform, which applies qPCR technology and extracellular vesicles to identify combinations of cancer-associated biomarkers.
BiotechHealthtechMedical Devices
Co-investorsiSelect FundMindshift CapitalNovalis LifeSciencesPortfoliaSozo VenturesThe Perkins Fund
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical Devices
Co-investorsARCH Venture Partners8VCNewpath Partners
Nursegrid is a mobile app for nurses to manage their work schedules, connect with colleagues, and stay organized.
ConsumerDigital HealthHealthtechHR TechSaaS
Co-investorsExcelerate Health VenturesPortland Seed FundToba Capital
NuSirt Sciences develops therapies that activate the sirtuin pathway by combining established pharmaceuticals and natural products to treat cardiometabolic conditions of aging and overnutrition, including fatty liver disease (MAFLD/MASH), obesity, type 2 diabetes, and hypertension.
BiotechHealthtechLongevityNashville, US
Michael Zemel(Executive Officer, Director)Barbara Cannon(Executive Officer)Joseph C. Cook, Jr.(Executive Officer, Director)
BoardEric Satz(Director)Vaughn Bryson(Director)Brian Laden(Director)
Co-investorsMountain Group Capital
Co-investorsThe Launch Place
Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.
BiotechMedical DevicesSan Francisco, US
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Co-investorsAccess BiotechnologyCatalio Capital Management, LPLAVLilly Asia VenturesOrbiMedHatteras
Pharaoh Neuro is a neurotechnology company focused on protecting and restoring brain health, with an emphasis on the fluids surrounding the brain such as cerebrospinal fluid.
BiotechDeep TechHealthtechMedical Devices
Mark Wagner(Founder, Investor, & Director)inAmaza Reitmeier(CEO)
Co-investorsArboretum VenturesIAG Capital Partners
Pryon provides a memory layer platform that helps enterprises move AI projects into production by ingesting, governing, and securing content across multiple formats and sources.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise Software
Co-investors7BC Venture CapitalAperture Venture CapitalDuke Capital PartnersGood Growth CapitalGreycroftIronGate Capital Advisors+4 more
QpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria.
BiotechHealthtechSan Diego, US
Michael N. Dudley(Executive Officer, Director)Terry Gould(Director)Daniel Burgess(Director)
BoardCarol Gallagher(Director)Douglas Reed(Director)Kevin Li(Director)
Co-investorsLYZZ CapitalNew Enterprise Associates (NEA)
Co-investorsKensington Capital Partners LimitedWhitecap Venture Partners
Medical technology company developing next-generation stroke aspiration technology
Co-investorsEpidarex Capital
RapidPulse is a medical device company developing technology for the treatment of ischemic stroke, currently conducting a pivotal clinical study.
BiotechHealthtechMedical Devices
Co-investorsBroadview VenturesEpidarex Capital
HealthtechDurham, US
Cambre Kelly(Executive Officer)Kenneth Gall(Executive Officer, Director)Kurt Jacobus(Executive Officer, Director)Andrew Miller(Executive Officer)Michael Fillion(Executive Officer)Greg Anglum(Executive Officer)
Co-investorsDuke Capital Partners
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health InvestorsDementia Discovery Fund+1 more
HealthtechCambridge, US
Adam Rosenberg(Executive Officer, Director)
BoardBruce Booth(Director)Kees Been(Director)Samantha Singer(Director)
Co-investorsGV (Google Ventures)Third Point VenturesAtlas VentureJJDCRemeditex Ventures
Roobrik provides science-based online surveys, financial-readiness assessments, and chat tools that help prospective senior living residents and their families evaluate their options while converting more website visitors into qualified leads for senior living providers.
Digital HealthHealthtechMarketing TechSaaSSales TechGreensboro, US
Nathaniel O'Keefe(Executive Officer, Director)Nate O'Keefe(Founder)inJudith Conaway(Executive Officer)David Levin(Director)Maureen O'Connor(Director)William Clark(Director)
Co-investorsIDEA NCJurassic CapitalThe Launch PlaceThird Act Ventures
Rx Redefined provides a platform and management services for DMEPOS (durable medical equipment, prosthetics, orthotics, and supplies) ordering, handling revenue cycle processes, compliance checks, and audit processing for physicians.
BiotechDigital HealthHealthtechMedical DevicesSaaSArroyo Grande, US
Brandon Boots(Founder & CEO)Erik Smith(Executive Officer, Director)
BoardIan Chiang(Director)inRoger Chen(Director)in
Co-investorsCrosscut VenturesFlare Capital PartnersSilverton PartnersSaturn FiveTusk Venture Partners
SafeRide Health provides non-emergency medical transportation (NEMT) through a technology platform and a nationwide network of transport and rideshare providers, connecting patients — largely Medicare Advantage and Medicaid members — to healthcare appointments.
Digital HealthHealthtechMobility & Transportation
Co-investorsBonfire VenturesFCA Venture PartnersFresenius Medical Care VenturesHDS CapitalLayout VenturesMeridian Street Capital+5 more
Enterprise retention-marketing and personalization platform for publishers, retailers and ecommerce brands, acquired by Campaign Monitor/CM Group in 2018 and now owned and sold by Zeta Global.
SaaSNew York, US
Neil Capel(Co-founder, Chief Executive Officer; later Chairman)Ian White(Co-founder and Chief Technology Officer)Chris Chapman(Co-founder / engineering leader)Amy Shapero(Chief Financial Officer)Neil Lustig(Chief Executive Officer)
BoardStacey Bishop(Board Director (Scale Venture Partners))in
Co-investorsBowery CapitalRunway Venture PartnersThrive CapitalBenchmarkRRE VenturesScale Venture Partners
Co-investorsCorewell Health Ventures
Sensorium Therapeutics is a clinical-stage biotech company developing novel CNS therapies for anxiety, epilepsy, and cognitive dysfunction using its SensAI platform, which integrates AI, chemistry, and curated natural product data to identify therapeutic patterns from over 50 million biological relationships.
AI & Machine LearningBiotechDigital HealthMedford, US
Jerrold Rosenbaum(Director)inJacob Hooker(Executive Officer, Director)inPranav Tadi(Executive Officer)
BoardRyan Katz(Director)inKevin Lalande(Director)inRichard Simon(Director)
Co-investorsBonaventure Equity, LLCIter InvestmentsMission BiocapitalRoute 66 VenturesService Provider CapitalSante Health Ventures
Standard Bariatrics develops the Titan SGS™ Stapler, a specialized surgical device designed for sleeve gastrectomy procedures that creates consistent and symmetrical gastric pouches using an anatomy-based approach.
Medical Devices
Co-investorsCincyTechEmergent Medical Partners, LLPJobsOhio VenturesRC CapitalRiverVest Venture PartnersUS Venture Partners
Synaptrix develops NOVABLOC, a non-opioid neuromodulation therapy that uses electrical stimulation to provide targeted, long-lasting postoperative pain relief.
BiotechDigital HealthMedical DevicesAlpharetta, US
Shyamy Sastry(Executive Officer, Director)
BoardDoug Reed(Director)Robert Crutchfield(Executive Officer, Director)Anita Watkins(Director)Kurt Jacobus(Director)
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)Marcel Frenkel(Executive Officer, Director)Damien Petty(Director)Jia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersAlexandriaHatteras+2 more
Co-investorsWolfpack Investor Network
Co-investorsWolfpack Investor Network
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Executive Officer)Derek Jantz(Executive Officer)inCharles Gersbach(Director)inJohn McHutchison(CEO, Chairman of the Board)Dan McHugh(Executive Officer, Director)Blythe Sather(Executive Officer)
Co-investorsDuke Capital PartnersMission BiocapitalNew Enterprise Associates (NEA)Yosemite
Durham, US
Jesko von Windheim(Executive Officer, Director)Richard N. Scott(Executive Officer)Timothy S. Tracey(Executive Officer, Director)Jill Marcotte(Director)Matt Bittner(Director)
Co-investorsDuke Capital Partners
Co-investorsSanofi Ventures
Co-investorsPappas Capital
AgTechDurham, US
Tracy Jackson(Executive Officer)John Riley(Director)Joel Marcus(Director)John Dombrosky(Executive Officer, Director)
Co-investorsS2G Investments
Vital Plan sells herbal supplements and nutrient formulas aimed at supporting cellular health and overall wellness, including its RESTORE180 program for people managing chronic health challenges.
ConsumerDirect to ConsumerWellness & FitnessRaleigh, US
Braden Rawls(Executive Officer, Director)William Rawls(Director)Dr. Bill Rawls(Co-founder)
BoardWalter Clarke(Director)
Co-investorsThe Launch Place
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 5
IPOs and acquisitions across the tracked portfolioAlkermesNASDAQ: ALKSAN2 TherapeuticsNASDAQ: ANTXCVRxNASDAQ: CVRXKymera TherapeuticsNASDAQ: KYMRShattuck LabsNASDAQ: STTK
Portfolio news
latest coverage across their companiesAN2 Therapeutics · ng.investing.com · Aug 19, 2026
Shattuck Labs · stocktitan.net · Aug 14, 2026
SafeRide Health · trysignalbase.com · Jul 28, 2026
Pharaoh Neuro · massdevice.com · Jul 24, 2026
Ladder · healthcareittoday.com · Jul 17, 2026
Alkermes · biospace.com · Jul 15, 2026
CVRx · tradersunion.com · Jul 7, 2026
Caidya · pharmasource.global · Jul 1, 2026
Fund performance · per public LP disclosures · 2
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Hatteras Venture Partners VLPs: San Diego City Employees' Retirement System | 2015 | — | 35.3% | 2.08x | 1.35x |
| Hatteras Venture Partners III, L.P.LPs: North Carolina Retirement Systems | 2007 | — | 0.3% | — | — |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Public market activity · per SEC filings
what is this? ⓘDisclosed stake · filed Feb 2023
Disclosed stake · filed Jan 2023
Disclosed stake · filed Dec 2019
Disclosed stake · filed Jul 2019
Disclosed stake · filed Jul 2019
Disclosed stake · filed Nov 2018
Disclosed stake · filed Nov 2018
Disclosed stake · filed Mar 2018
Disclosed stake · filed Apr 2017
Disclosed stake · filed Feb 2017
Disclosed stake · filed Jun 2016
5 insider ownership filings (Forms 3/4/5)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Hatteras Venture Partners made?
- Hatteras Venture Partners has 62 tracked investments, 1 of which have exited via acquisition or IPO, including 6 dated in the last 24 months.
- What stage does Hatteras Venture Partners invest at?
- Hatteras Venture Partners invests at the Seed, Series A, Series B, Series C stages.
- What is Hatteras Venture Partners's typical check size?
- Hatteras Venture Partners typically writes checks of $500K – $4M.
- What sectors does Hatteras Venture Partners focus on?
- Hatteras Venture Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Medical Devices.
- Where is Hatteras Venture Partners located?
- Hatteras Venture Partners is headquartered in Research Triangle, US.
- Does Hatteras Venture Partners lead rounds?
- Hatteras Venture Partners typically participates in rounds rather than leading them.
- Who does Hatteras Venture Partners co-invest with?
- Hatteras Venture Partners most often shares deals with OrbiMed, Excelerate Health Ventures, OUP (Osage University Partners), among 71 tracked co-investors.
Images
Co-investors · 23
Arboretum Ventures is a Midwest-based healthcare venture capital firm that invests in early-stage healthcare startups across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Broadview Ventures is an impact investor focused on accelerating the development of technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
Fusion Fund is an early-stage venture capital firm backing startups with technical or data advantages in healthcare, enterprise AI, and industrial technology.
Morpheus Ventures is a venture capital fund that backs early-stage companies and supports founders through the challenges of scaling toward hyper-growth.
▶11 more co-investors
Toba CapitalCatalio Capital Management, LPMayfield Fund5AM VenturesJohnson & Johnson Innovation – JJDCRebel FundPJCOmega FundsRoche Venture FundJDRF T1D FundAbbVie
Firms observed investing alongside Hatteras Venture Partners, from public investor directories. Shared companies are the overlap with Hatteras Venture Partners's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.